These unexpected findings suggest that combination therapy of liver disease patients with inflammation and fibrosis complications with both the FXR agonist OCA and a BET protein inhibitor like JQ1 may lead to unfavorable clinical outcomes. The gene discussed is NR1H4; the disease is liver disorder.